Fintel reports that on January 29, 2025, Truist Securities initiated coverage of Larimar Therapeutics (NasdaqGM:LRMR) with a Buy recommendation. As of January 29, 2025, the average one-year price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback